Printer Friendly

Electrophysiological and Structural Changes in Chinese Patients with LHON.

1. Introduction

Leber hereditary optic neuropathy (LHON) was first described by Theodor Leber in 1871 [1] and is one of the most common disorders caused by mitochondrial DNA (mtDNA) mutation. Over 95% of LHON pedigrees harbor one of three mtDNA point mutations (G3460A, G11778A, and T14484C), which all involve genes encoding complex I subunits of the mitochondrial respiratory chain [2]. The retinal ganglion cell (RGC) system is particularly vulnerable to mitochondrial dysfunction, and optic atrophy is a frequent characteristic of mitochondrial and neurodegenerative diseases [3, 4]. An intriguing feature of LHON is that approximately only 50% of males and 10% of females who harbor a pathogenic mtDNA mutation develop optic neuropathy. Pathogenic mtDNA mutations are necessary for the development of LHON, but other factors must be responsible for the variable penetrance and the male predominance of the condition. Studies have examined the possible influence of an X-linked visual loss susceptibility locus, impaired mitochondrial respiratory chain activity, mtDNA heteroplasmy, environmental factors, and autoimmune factors [5, 6]. The clinical characteristics of LHON are well documented [7-10], but fewer studies have compared visual electrophysiology with optical coherence tomography (OCT) of the retinal ganglion cell layer (GCL) and retinal nerve fiber layer (RNFL) in different stages of the disease. The aim of this study is to compare the retinal structure and function in both the acute and chronic stages of LHON in Chinese patients. The influence of the disease stage is examined by detailed OCT measures of macular and peripapillary retinal structure and by comprehensive electrophysiology, including pattern and multifocal electroretinography (PERG; mfERG).

2. Materials and Methods

Thirteen Chinese patients with LHON were ascertained in the Department of Ophthalmology at the Southwest Hospital in Chongqing between April 2013 and April 2015. Informed consent was obtained from all patients. Each subject was treated in accordance with the tenets of the Declaration of Helsinki and the study was approved in advance by the Ethics Committee of Third Military Medical University, Chongqing, China.

There were 11 male and 2 female patients with a median age of 18 years (range 8-43 years). Patients were divided into two groups according to the disease duration: group 1 (acute stage; duration less than 3 months) and group 2 (chronic stage; duration 3 months to 18 years). The duration was measured from and the date of onset of visual symptoms, as reported by the patients at presentation. Group 1 included 7 eyes and group 2 included 19 eyes. One patient examined in the acute stage was monitored for 3 years. All patients were screened for the 7 primary and 9 secondary mtDNA mutations, most commonly involved in LHON as reported in ITOMAP (

Subjects underwent a clinical and ophthalmological examination including visual acuity assessment, fundoscopy, fundus fluorescein angiography (FFA), macular, and peripapillary OCT. The OCT (Topcon3D-1000, Topcon Corporation, Japan) was performed on the macula (6 mm x 6 mm; centered on the fovea) and a macular thickness map used to measure the thickness of the retinal ganglion cell layer plus inner plexiform layer (GCL + ICL) and the thickness of the retinal nerve fiber layer (RNFL). Scanning of the peripapillary area was used to assess the RNFL layer surrounding the optic disc (RNFL-OCT).

Electrophysiological investigations included full-field electroretinography (FERG), PERG, and visual evoked potential (VEP) testing (Espion system, Diagnosys LLC, Lowell, MA, USA). Multifocal ERG testing was additionally performed using a 103-element scaled stimulus array. The mfERG system incorporated a real-time fundus camera, allowing fixation-dependent stimulus placement to be monitored during the examination (Veris system, Electro-Diagnostic Imaging, Inc., Burlingame, CA, USA; CCD Camera, Hitachi Kokusai Electric Inc, Japan). All tests were performed according to the International Society for Clinical Electrophysiology of Vision (ISCEV) Standards [11-14], with the exception of the PERG, performed using a large stimulus field size (24 degrees x 18 degrees). Recordings were compared with normal laboratory-specific controls. Differences between patients and age-matched controls were tested statistically using an independent two-sample t-test performed in SPSS Statistics software (Version 19, IBM, Armonk, NY, USA).

3. Results

Genetic testing revealed mtDNA mutation 11778 in seven patients, 3460 in two, 3497 in two, and mutations 3635 and 3316 in one, and mutation 3394 in one patient.

The clinical and electrophysiological characteristics of the patients are summarized in Table 1. Visual acuity was severely impaired in all patients. On fundoscopy, there was optic disc hyperemia in Group 1 (all 7 eyes) and disc pallor in Group 2 (all 19 eyes; see Figure 1 for examples). Visual field testing showed central defects and blind spot enlargement in all patients.

The OCT data are summarized in Table 2. The RNFL thickness around the optic disc was normal in group 1 and abnormal in group 2. RNFL thickness surrounding the macula was normal in group 1 compared to controls but reduced significantly in group 2. The thickness of the GCL + IPL layer surrounding macula was reduced in both groups compared with normal (Table 2; Figure 2). An example of macular OCT, performed in the acute and chronic stages in a single individual, is shown in Figure 3.

Pattern ERG P50 amplitude was normal in both groups, but the N95/P50 ratio was reduced significantly in group 1 and group 2 compared with the (normative) control group (Figure 2; Table 3; p < 0.001 for each group). The N95/P50 ratio was more severely reduced in most group 2 compared with group 1 cases. The P50 peak time was normal in group 1 but was abnormally shortened in most eyes in group 2 with a mean difference from the normal mean of 4.7 ms (Figure 2; Table 3; acute vs control, p = 0.141; chronic vs control, p = 0.001). An example of pattern ERG data recorded from one individual is shown in Figure 4.

Examples of mfERGs recorded in groups 1 and 2 are shown in Figures 4 and 5 and all mfERG data are summarized in Table 4. The amplitude density of the central (ring 1 and 2) multifocal ERG in group 1 was significantly subnormal in 4 and 3 of 5 eyes compared with the control data, respectively (Table 4; p < 0.01, p < 0.05); responses in Ring 3 to Ring 6 were not significantly reduced (p > 0.01). In Group 2, the amplitude density in Rings 1, 2, and 3 was significantly reduced in 16, 15, and 13 of 17 eyes, respectively (Table 4; p < 0.001); responses in Rings 4 to 6 were not significantly different from normal (p > 0.01). The mfERG reductions in Rings 1 and 2 were significantly more severe in group 2 compared with group 1 (p < 0.05). Structural and functional changes are summarized in Table 5, including measurements of RNFL and GCL + IPL thickness in the macular OCT, PERG P50, and N95/P50 ratio changes, and mfERG amplitude reductions.

The amplitude of the pattern reversal VEP P100 component was decreased and the peak time delayed by a mean of 19.5 ms in 5/5 eyes in group 1; responses were undetectable in 3/8 eyes in group 2, and in the other 5 eyes the amplitude was decreased and the peak times delayed by a mean of 21.1 ms. The ISCEV-standard full-field ERG components were normal in all patients in both groups. There was no significant correlation between the severity of VEP, PERG, and mfERG abnormalities.

4. Discussion

This study compares cases of genetically confirmed LHON in acute and chronic stages according to detailed OCT scans of the macula and peripapillary regions and according to comprehensive electrophysiological measures of retinal function, including the pattern ERG, full-field ERG, and multifocal ERG. Both acute and chronic groups show OCT evidence of inner retinal loss and both show PERG N95 reduction consistent with RGC dysfunction. In chronic cases, there is additional macular and peripapillary RNFL loss associated with more severe RGC dysfunction in most, manifest as PERG N95 reduction and shortening of P50 timing. A novel finding is that 20 of 21 cases show mfERG evidence of additional localized central macular dysfunction, more severe and extensive in chronic than in acute cases.

LHON is one of the most common primary mitochondrial DNA (mtDNA) disorders. Retinal ganglion cells (RGCs) are exquisitely sensitive to mitochondrial dysfunction, and the papillomacular bundle is affected early and severely in LHON. The preferential involvement of the RGCs within the papillomacular bundle is likely related to the relatively small calibre of the axons and limited mitochondrial energy reserves [15]. Two major mechanisms have been proposed to precipitate RGC loss in LHON: a biochemical respiratory chain defect and increased levels of reactive oxygen species (ROS) [16]. Not all LHON mutation carriers will experience visual loss during their lifetime. Three mtDNA point mutations (G3460A, G11778A, and T14484C), which all involve complex I subunits of the mitochondrial respiratory chain, account for the vast majority of LHON cases, as reported in MITOMAP (http:// Rarer mtDNA mutations have also been confirmed as causing the LHON phenotype, having been reported in more than one pedigree, and showing clear segregation with affected disease status. In our study, 9 patients carried G3460A or G11778A mutation but none were identified that carried the T14484C mutation, possibly due to the small sample size. Other studies have identified Chinese patients with LHON that harbor the T14484C mutation [17].

Fundoscopy showed optic disc hyperemia in the acute stage ([less than or equal to] 3 months from onset) in patients with LHON and optic atrophy in the chronic stage (>3 months from onset). Central field defects and blind spot enlargement were common findings, in keeping with previous investigations [18]. The current study showed that that the thickness of the RNFL around the optic disc and surrounding the macula did not reduce in the acute stage but reduced significantly in the chronic stage of the disease, corroborating previous reports [19, 20].

The pattern ERG N95 and approximately 70% of P50 originate in the retinal ganglion cells. There was a marked reduction in the PERG N95/P50 ratio in both acute and chronic LHON groups, indicating RGC dysfunction and consistent with thinning of GCL + IPL layer. PERG N95 loss can occur in other forms of optic neuropathy but usually in longstanding disease (minimum 4-6 weeks but often longer) due to retrograde degeneration of the RGCs; N95 reduction in the acute stages for all patients is in keeping with primary ganglion cell disease. Additional shortening of P50 was a consistent feature in those with a history of LHON longer than 3 months, likely representing an additional loss of the RGC contribution to P50 and consistent with relatively rapid progression and worsening involvement of the RGCs.

A novel finding was that mfERG showed a reduction over central areas in both acute and chronic cases. Multifocal ERGs can be influenced by poor fixation, particularly if vision is impaired, but in the current study the mfERG system incorporated a fundus camera, allowing fixation-dependent stimulus placement on the fundus to be monitored during the examination. The mfERG scalar plots and relative preservation of PERG P50 (Figure 4) are consistent with adequate central fixation. The mfERG N1 and P1 components arise largely in the On and Off bipolar cells with a cone photoreceptor contribution to N1 [21]. The abnormal mfERGs suggest dysfunction of either the macular cones or macular bipolar cells in the absence of fundus change (an occult maculopathy) or a previously unsuspected contribution of the RGCs to the first-order mfERG. It is notable that macular dysfunction was not severe enough to significantly attenuate the PERG P50, presumably due to lower spatial resolution of the large-field PERG technique. An important implication is that macular dysfunction may contribute to visual acuity reduction and may influence other psychophysical tests of central macular function and pattern VEP findings. The latter tests are often used in the assessment of optic neuropathy and RGC dysfunction and may be used to monitor disease progression or treatment efficacy. The severity of pattern VEP abnormalities in the current study may largely be due to optic nerve dysfunction but may also partly be attributable to occult maculopathy. In LHON, RGC dysfunction maybe of primary importance but it would seem prudent to additionally monitor macular cone and bipolar cell function objectively, to better understand and more accurately monitor the pathophysiology of disease and potential efficacy of future treatments.

The study highlights differences in retinal structure and function between the acute and chronic stages that are pertinent to investigations that aim to monitor disease severity and progression or efficacy of future treatments. The visual prognosis in LHON is poor and most patients remain legally blind. Owing to the limited understanding of the mechanisms of LHON, treatment options are still in their infancy. Supportive measures, such as low-vision aids and recognition and therapy of associated treatable systemic abnormalities, remain the primary focus for the clinician. Idebenone (a quinone analog of coenzyme Q10) has been reported to be effective in increasing the rate of recovery in LHON especially in patients with discordant visual acuity and if the patients are treated early in the disease course [22] As a better understanding of the pathophysiology is gained, novel, more-effective therapies are likely to emerge, and more targeted treatments developed. The ongoing development of animal models for the hereditary optic neuropathies will facilitate the translation from bench to bedside. Gene therapy is particularly encouraging for those patients whose phenotypic expression is limited to the optic nerve and retinal ganglion cells, as the affected neurons are anatomically accessible to directed therapy [23-27]. The value of the comprehensive electrophysiological assessment is highlighted, for objectively characterizing the levels and severity of dysfunction within the retina, and for the objective monitoring of efficacy in future therapeutic interventions.

Data Availability

The clinical data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare they have no conflicts of interest.


The authors are grateful to Thomas M. Hall and Richard Smith for proofreading early versions of the manuscript and to Qing Wang, Ming Fang Zhang, and Cheng Sun for their technical support. This work was supported by the National Nature Science Foundation of China (81974138), the Third Military Medical University (Army Medical University) research grant (2017XYY02), and Chongqing Social and livelihood Science Innovation grant (cstc2017shmsA130100). A. G. Robson is supported by the NIHR Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology.


[1] T. Leber, "Ueber hereditare und congenital-angelegte sehnervenleiden," Albrecht Von Grxfe's Archiv fur Ophthalmologie, vol. 17, no. 2, pp. 249-291, 1871.

[2] D. A. Mackey, R. J. Oostra, T. Rosenberg et al., "Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy," American Journal of Human Genetics, vol. 59, pp. 481-485, 1996.

[3] V. Carelli, C. La Morgia, M. L. Valentino, P. Barboni, F. N. Ross-Cisneros, and A. A. Sadun, "Retinal ganglion cell neurodegeneration in mitochondrial inherited disorders," Biochimica et Biophysica Acta (BBA)--Bioenergetics, vol. 1787, no. 5, pp. 518-528, 2009.

[4] P. Yu-Wai-Man, P. G. Griffiths, and P. F. Chinnery, "Mitochondrial optic neuropathies--disease mechanisms and therapeutic strategies," Progress in Retinal and Eye Research, vol. 30, no. 2, pp. 81-114, 2011.

[5] R. M. Chalmers and A. H. V. Schapira, "Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy," Biochimica et Biophysica Acta (BBA)--Bioenergetics, vol. 1410, no. 2, pp. 147-158, 1999.

[6] P. Y. W. Man, D. M. Turnbull, and P. F. Chinnery, "Leber hereditary optic neuropathy," Journal of Medical Genetics, vol. 39, no. 3, pp. 162-169, 2002.

[7] J. Guy, W. J. Feuer, V. Porciatti et al., "Retinal ganglion cell dysfunction in asymptomatic G11778A: Leber hereditary optic neuropathy," Investigative Opthalmology & Visual Science, vol. 55, no. 2, pp. 841-848, 2014.

[8] D. A. Mackey, "Three subgroups of patients from the United Kingdom with Leber hereditary optic neuropathy," Eye, vol. 8, no. 4, pp. 431-436, 1994.

[9] A. Majander, A. G. Robson, C. Holder et al., "The pattern of retinal ganglion cell dysfunction in leber hereditary optic neuropathy," Mitochondrion, vol. 36, no. 9, pp. 138-149, 2017.

[10] N. Balducci, G. Savini, M. L. Cascavilla et al., "Macular nerve fibre and ganglion cell layer changes in acute Leber's hereditary optic neuropathy," British Journal of Ophthalmology, vol. 100, no. 9, pp. 1232-1237, 2016.

[11] M. Bach, M. G. Brigell, M. Hawlina et al., "ISCEV standard for clinical pattern electroretinography (PERG): 2012 update," Documenta Ophthalmologica, vol. 126, no. 1, pp. 1-7, 2013.

[12] J. V. Odom, M. Brigell, M. Bach et al., "ISCEV standard for clinical visual evoked potentials: (2016 update)," Documenta Ophthalmologica, vol. 133, no. 1, pp. 1-9, 2016.

[13] D. L. McCulloch, M. F. Marmor, M. G. Brigell et al., "ISCEV Standard for full-field clinical electroretinography (2015 update)," Documenta Ophthalmologica, vol. 130, no. 1, pp. 1-12, 2015.

[14] D. C. Hood, M. G. Brigell, M. Bach et al., "ISCEV standard for clinical multifocal electroretinography (mfERG2011 edition)," Documenta Ophthalmologica, vol. 124, no. 1, pp. 1-13, 2011.

[15] A. Maresca, C. La Morgia, L. Caporali, M. L. Valentino, and V. Carelli, "The optic nerve: a "mito-window" on mitochondrial neurodegeneration," Molecular and Cellular Neuroscience, vol. 55, pp. 62-76, 2013.

[16] V. Carelli, M. Rugolo, G. Sgarbi et al., "Bioenergetics shapes cellular death pathways in Leber's hereditary optic neuropathy: a model of mitochondrial neurodegeneration," Biochim Biophys Acta, vol. 1658, no. 1-2, pp. 172-179, 2004.

[17] Y. Li, J. Li, X. Jia, X. Xiao, S. Li, and X. Guo, "Genetic and clinical analyses of DOA and LHON in 304 Chinese patients with suspected childhood-onset hereditary optic neuropathy," PLoS One, vol. 12, no. 1, Article ID: e0170090, 2017.

[18] R. Ran, S. Yang, H. He et al., "A retrospective analysis of characteristics of visual field damage in patients with Leber's hereditary optic neuropathy," SpringerPlus, vol. 5, no. 1, pp. 843-849, 2016.

[19] S. J. Moster, M. L. Moster, M. S. Bryan, and R. C. Sergott, "Retinal ganglion cell and inner plexiform layer loss correlate with visual acuity loss in LHON: a longitudinal, segmentation OCT analysis," Investigative Opthalmology & Visual Science, vol. 57, no. 8, pp. 3872-3883, 2016.

[20] Y. Zhang, H. Huang, S. Wei et al., "Characterization of macular thickness changes in Leber's hereditary optic neuropathy by optical coherence tomography," BMC Ophthalmology, vol. 14, no. 105, pp. 105-111, 2014.

[21] D. C. Hood, L. J. Frishman, S. Saszik et al., "Retinal origins of the primate multifocal ERG: implications for the human response," Investigative Ophthalmology & Visual Science, vol. 43, no. 5, pp. 1673-1685, 2002.

[22] V. Carelli, C. Lamorgia, M. L. Valentino et al., "Idebenone-treatment in Leber's hereditary opticneuropathy," Brain, vol. 134, no. 9, p. e188, 2011.

[23] M. I. G. Lopez Sanchez, J. G. Crowston, D. A. Mackey, and I. A. Trounce, "Emerging mitochondrial therapeutic targets in optic neuropathies," Pharmacology & Therapeutics, vol. 165, no. 9, pp. 132-152, 2016.

[24] N. J. Newman, "Treatment of hereditary optic neuropathies," Nature Reviews Neurology, vol. 8, no. 10, pp. 545-556, 2012.

[25] P. Yu-Wai-Man, M. Votruba, A. T. Moore, and P. F. Chinnery, "Treatment strategies for inherited optic neuropathies: past, present and future," Eye, vol. 28, no. 5, pp. 521-537, 2014.

[26] S. Yang, S.-Q. Ma, X. Wan et al., "Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy," EBioMedicine, vol. 10, pp. 258-268, 2016.

[27] J.-J. Yuan, Y. Zhang, L.-L. Wang et al., "Visual field variability after gene therapy for Leber's hereditary optic neuropathy," Ophthalmic Research, vol. 60, no. 3, pp. 176-184, 2018.

Min Wang [ID], (1) Hong Guo, (2) Shiying Li [ID], (1) Gang Wang, (1) Yanling Long, (1) Xiaohong Meng, (1) Bo Liu, (1) Yong Liu [ID], (1) Anthony G. Robson, (3,4) and Zheng Qin Yin [ID] (1)

(1) Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Military Medical University), Chongqing, China

(2) Department of Medical Genetics, Third Military Medical University (Army Military Medical University), Chongqing, China

(3) Department of Electrophysiology, Moorfields Eye Hospital, London, UK

(4) Institute of Ophthalmology, University College London, London, UK

Correspondence should be addressed to Shiying Li;

Received 16 December 2019; Accepted 5 March 2020; Published 1 April 2020

Academic Editor: Arturo Carta

Caption: Figure 1: Color fundus photographs and corresponding visual fields obtained from patient 1 listed in Table 1. (a) Fundus photo, (b) visual field at acute stage (1 month after onset), (c) fundus photo, and (d) visual field at chronic stage (5 months after onset). Left eye, 16 years old, BCVA: 6/120 (acute stage); 6/300 (chronic stage).

Caption: Figure 2: (a) Pattern ERG P50 amplitude, (b) P50 peak timing, (c) N95/P50 ratio, and (d) the GCL + IPL thickness surrounding macula of all the eyes that underwent testing were plotted. The N95/P50 ratio reduced significantly in group 1 and group 2 compared with normal (p < 0.001 for each group) and more severely reduced in most group 2, consistent with thinning of GCL + IPL thickness surrounding macula. Individuals from each group are numbered (abscissa) and plotted as crosses (acute group/group 1) and open circles (chronic group/ group 2). Red line in each picture means average normal value. And the normal range is average normal value [+ or -] SD of each index.

Caption: Figure 3: Macular thickness OCT obtained from patient 1 in Table 1. (a) Acute stage, no reduced RNFL layer thickness around macula, reduced GCL + IPL layer thickness. (b) Chronic stage, reduced RNFL layer thickness around macula, and GCL + IPL layer thickness. Left eye, 16 years old, BCVA: 6/120 (acute stage); 6/300 (chronic stage).

Caption: Figure 4: Electrophysiological recordings obtained from patient 1 in Table 1. (a) PERG, (b) PVEP, (c) mfERG at acute stage, (d) PERG, (e) PVEP, (f) mfERG at chronic stage, (g) PERG, (h) PVEP, and (i) mfERG of normal control eye. The N95 component amplitude reduced both in the acute and chronic stage. The amplitude density of inner rings of the MFERG reduced both in the acute and chronic stages. BCVA: 6/120 (acute stage); 6/300 (chronic stage). PERG recordings were reproducible.

Caption: Figure 5: Examples of trace array in mfERG in both acute and chronic stage. (a, b) Two eyes at acute stage, (c, d) two eyes at chronic stage, (e) normal eye, and (f) eye fundus monitoring with camera when recording the traces. As shown above, amplitude density reduced in the inner rings in both the acute and chronic stages.
Table 1: Summary of genetic, functional, and structural findings in
patients with LHON.

          Patient                           Gene      Snellen
          number    Gender   Eye   Age    mutation     BCVA

Acute        1        M       L    16      11778       6/120
Chronic      1        M       R    16      11778       6/300
Acute        2        M       R    14      11778       6/150
Acute        2        M       L    14      11778       6/40
Acute        3        M       R    13    3635, 3316    6/150
Acute        3        M       L    13    3635, 3316    6/200
Acute        4        M       R    38       3497        CF
Acute        4        M       L    38       3497       6/600
Chronic      5        M       R    19      11778       6/200
Chronic      5        M       L    19      11778       6/200
Chronic      6        F       R    18       3460       6/40
Chronic      6        F       L    18       3460       6/60
Chronic      7        M       R    15      11778        CF
Chronic      7        M       L    15      11778       6/600
Chronic      8        F       L    43       3460       6/20
Chronic      8        F       R    43       3460       6/120
Chronic      9        M       L    38      11778       6/300
Chronic      9        M       R    38      11778        CF
Chronic     10        M       L     8       3394       6/600
Chronic     10        M       R     8       3394       6/60
Chronic     11        M       L    29       3497        6/9
Chronic     11        M       R    29       3497       6/60
Chronic     12        M       L    18      11778       6/60
Chronic     12        M       R    18      11778        CF
Chronic     13        M       L    41      11778       6/600
Chronic     13        M       R    41      11778       6/60

            PVEP                    PERG                       mfERG

          Peak time      P50       N95/P50                   Ring 1-2
           delayed    amplitude   amplitude   Peak time      amplitude
           (ms) *      reduced     reduced    shortening     decreased

Acute        35           -           +       -                  +
Chronic                   -           +       +                  +
Acute        20           -           +       -                  +
Acute        16           -           -       -                  +
Acute        12           -           +       -                  +
Acute        12           -           +       -                  -
Chronic                   -           +       +                  +
Chronic                   -           +       +                  +
Chronic      18           -           +       +                  +
Chronic      19           -           +       +                  +
Chronic      27           -           +       +                  +
Chronic      25           -           +       +                  +
Chronic                                                          +
Chronic                                                          +
Chronic                   -           +       +                  +
Chronic                   +           +       +                  +
Chronic                                                          +
Chronic                                                          +
Chronic                                                          +
Chronic                   -           +       +                  +
Chronic                   -           +       +                  +


           GCL + IPL       RNFL         RNFL
           thickness     thickness      around
          thinning in   thinning in   optic disc
            macula        macula

Acute          +             +            -
Chronic        +             +            +
Acute          +             -
Acute          +             -
Acute          +             -            -
Acute          +             +            -
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +
Chronic        +             +
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +            +
Chronic        +             +            +

Notes: signifies normal findings; "+" signifies abnormal findings;
absence of data indicates that tests were not performed; "CF"
indicates "counting fingers visual acuity"; *PVEP peak time delay
indicates the time above the upper limit of normal in the age-matched
control group.

Table 2: Optical coherence tomography (OCT) measures of RNFL
thickness around the optic disc (GCL + IPL) and RNFL thickness
surrounding macula in group 1 (acute cases), group 2 (chronic cases),
and in the control group.

                                          Group 1

RNFL around     Number of eyes               3
optic disc      RNFL thickness       117 [+ or -] 12.1

                Number of eyes               5
Macula        GCL + IPL thickness   57.0 [+ or -] 4.9 *
thickness       RNFL thickness       31.8 [+ or -] 9.5

                                          Group 2

RNFL around     Number of eyes               13
optic disc      RNFL thickness      66.1 [+ or -] 16.2 *

                Number of eyes               15
Macula        GCL + IPL thickness   53.1 [+ or -] 2.5 *
thickness       RNFL thickness       7.2 [+ or -] 7.1 *

                                      Control group

RNFL around     Number of eyes              10
optic disc      RNFL thickness      105.7 [+ or -] 8.1

                Number of eyes              10
Macula        GCL + IPL thickness   71.7 [+ or -] 3.9
thickness       RNFL thickness      35.4 [+ or -] 3.9

RNFL thickness around optic disc did not reduce in group 1 but
reduced in group 2 (Group 1 vs. control, p = 0.08; group 2 vs.
control, p < 0.001*). The GCL + IPL thickness surrounding macular
area (6 mm x 6 mm, centered on fovea) reduced in both groups (Group 1
vs. control, p < 0.001*; group 2 vs. control, p < 0.001*). The RNFL
thickness surrounding macular area did not reduce in group 1 (p =
0.454), but reduced in group 2 (p < 0.001*). RNFL: retinal nerve
fiber layer; GCL + IPL: ganglion cell layer plus inner plexiform

Table 3: PERG P50 amplitude, N95/P50 ratio, and P50 peak time in
group 1 and group 2 compared with the normal group.

                 Eyes                   Group 1

       P50 amplitude ([micro]v)     4.6 [+ or -] 0.7
PERG        N95/P50 ratio         1.32 [+ or -] 0.11 *
          P50 peak time (ms)       51.0 [+ or -] 0.7

                 Eyes                   Group 2

       P50 amplitude ([micro]v)     4.5 [+ or -] 0.9
PERG        N95/P50 ratio         1.12 [+ or -] 0.16 *
          P50 peak time (ms)      44.9 [+ or -] 2.8 *

                 Eyes               Control group

       P50 amplitude ([micro]v)    5.2 [+ or -] 1.1
PERG        N95/P50 ratio         1.74 [+ or -] 0.17
          P50 peak time (ms)      49.6 [+ or -] 3.3

The PERG P50 component amplitude was normal compared with controls in
both groups (group 1 vs control, p = 0.278; group 2 vs control p =
0.128). The PERG N95/P50 ratio was significantly decreased in group 1
and group 2 compared with control group (p < 0.001* for each group).
P50 peak time was normal in group 1 and abnormally shortened in group
2 (group 1 vs control, p = 0.141; group 2 vs control p = 0.001*).

Table 4: Amplitude density of mfERG for 6 rings.

                                Group 1               Group 2

                 Ring 1   30.7 [+ or -] 8.5 *   20.1 [+ or -] 8.8 *
Amplitude        Ring 2   25.3 [+ or -] 7.6 *   18.0 [+ or -] 6.7 *
density          Ring 3    20.6 [+ or -] 6.1    16.8 [+ or -] 6.0 *
of MfERG         Ring 4    16.9 [+ or -] 4.9     15.1 [+ or -] 5.5
([micro]v/deg)   Ring 5    14.0 [+ or -] 4.4     14.2 [+ or -] 5.3
                 Ring 6    12.9 [+ or -] 4.4     13.7 [+ or -] 6.3

Number of eyes                     5                    17

                            Control group

                 Ring 1   42.2 [+ or -] 6.0
Amplitude        Ring 2   31.9 [+ or -] 3.2
density          Ring 3   23.9 [+ or -] 1.8
of MfERG         Ring 4   19.1 [+ or -] 1.6
([micro]v/deg)   Ring 5   16.1 [+ or -] 1.8
                 Ring 6   14.3 [+ or -] 2.5

Number of eyes                   10

In group 1, the mean amplitude density of rings 1 and 2 were reduced
significantly compared with controls (p = 0.009 *, p = 0.032 *
respectively). In group 2, the mean amplitude density of rings 1, 2,
and 3 were reduced significantly compared with controls (p < 0.001, p
< 0.001, and p < 0.001 *, respectively).

Table 5: Summary of structural and functional characteristics.

Group 1                        Group 2

Structural                   Structural
OCT RNFL normal           OCT RNFL reduced
(3 of 5 eyes)              (15 of 15 eyes)
OCT GCL + IPL reduced   OCT GCL + IPL reduced
(5 of 5 eyes)              (15 of 15 eyes)

Functional                   Functional
P50 normal                   P50 normal
(5 of 5 eyes)              (10 of 11 eyes)
N95/P50 reduced            N95/P50 reduced
(4 of 5 eyes)              (11 of 11 eyes)
AD of ring 1 reduced    AD of ring 1 reduced
(4 of 5 eyes)              (16 of 17 eyes)
AD of ring 2 reduced    AD of ring 1 reduced
(3 of 5 eyes)              (15 of 17 eyes)
AD of ring 3 reduced    AD of ring 1 reduced
(3 of 5 eyes)              (13 of 17 eyes)

Structural measures are shown for "OCT RNFL" (thickness of the RNFL in
macular OCT) and "OCT GCL + IPL" (thickness of GCL + IPL layer in
macular OCT). Functional measures include the pattern ERG P50
amplitude, N95: P50 amplitude ratio, and amplitude density (AD) of the
mfERG in ring 1 (fovea) and rings 2 and 3.
COPYRIGHT 2020 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Wang, Min; Guo, Hong; Li, Shiying; Wang, Gang; Long, Yanling; Meng, Xiaohong; Liu, Bo; Liu, Yong; Ro
Publication:Journal of Ophthalmology
Geographic Code:9CHIN
Date:Apr 30, 2020
Previous Article:Clinical and Epidemiological Study on Tubercular Uveitis in a Tertiary Eye Care Centre in Italy.
Next Article:Comparing Medium-Term Clinical Outcomes following XEN[R] 45 and XEN[R] 63 Device Implantation.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |